SCHEMBL6611228

SCHEMBL6611228

CCCc1ccc(S(=O)(=O)Nc2ccsc2CC(=O)N(C(C)C)C(C)C)cc1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
METAP2 P50579 1/20 0.42
FFAR4 Q5NUL3 1/20 0.42
LMNA P02545 2/20 0.41
HPGD P15428 1/20 0.41
TSHR P16473 1/20 0.41
ALDH1A1 P00352 5/20 0.40
KDM4E B2RXH2 2/20 0.40
MAPT P10636 1/20 0.39
ATM Q13315 1/20 0.39
GHSR Q92847 1/20 0.38
AKT1 P31749 3/20 0.38
IRS1 P35568 2/20 0.37
GAB1 Q13480 2/20 0.37
PSMB5 P28074 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
F2 P00734 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6609608 0.88 FFAR4 (0.45) METAP2FFAR4LMNAHPGDTSHR
SCHEMBL6610971 0.87 METAP2 (0.42) METAP2FFAR4LMNAHPGDTSHR
SCHEMBL20899670 0.85 ALDH1A1 (0.49) METAP2FFAR4LMNAHPGDTSHR
SCHEMBL6617568 0.83 GAA (0.45) LMNAHPGDTSHRMAPT
SCHEMBL6613051 0.80 FFAR4 (0.44) METAP2FFAR4LMNAALDH1A1KDM4E
SCHEMBL6612972 0.78 HPGD (0.53) LMNAHPGDTSHRALDH1A1MAPT
SCHEMBL6624267 0.77 ALDH1A1 (0.43) METAP2FFAR4LMNAHPGDTSHR
SCHEMBL3616155 0.77 KMT2A (0.55) ALDH1A1AKT1IRS1GAB1
SCHEMBL6623939 0.76 TSHR (0.54) LMNAHPGDTSHRALDH1A1MAPT
SCHEMBL5831678 0.76 AKT1 (0.44) FFAR4LMNAALDH1A1KDM4EAKT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1461333-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2004-09-29 EP claimed
US-20030130279-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2003-07-10 US claimed
WO-2003044009-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2003-05-30 WO claimed
WO-2004112779-A1 NEW USE VII BIOVITRUM AB (SE) 2004-12-29 WO disclosed
EP-1461333-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2004-09-29 EP disclosed
US-20030130279-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2003-07-10 US disclosed
WO-2003044009-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2003-05-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030130279-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD17B1, HSD3B1 METAP2 2185/4885FFAR4 3173/4885LMNA 1976/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.